Management of Beta-Blockers in Acute Kidney Injury

Introduction to Beta-Blocker Use in AKI

The American College of Cardiology recommends continuing metoprolol tartrate at the same dose in patients with AKI, as dose adjustment is not required based on kidney function 1
Metoprolol tartrate is primarily metabolized by the liver, making it a preferred beta-blocker in patients with impaired kidney function, with its elimination not significantly affected by reduced kidney function 1

Patients with AKI should be monitored for clinical efficacy and adverse effects, including heart rate control, blood pressure response, and signs of beta-blocker toxicity (bradycardia, hypotension) 1
In patients with severe AKI requiring renal replacement therapy, standard dosing of metoprolol tartrate can still be maintained 1
For patients with hepatic impairment in addition to AKI, dose reduction of metoprolol tartrate may be necessary as it is primarily metabolized by the liver 1

Metoprolol tartrate is the preferred beta-blocker in AKI patients, as it does not require dose adjustment in AKI 1
Atenolol, nadolol, and acebutolol should be used with caution in AKI patients, as they require dose adjustment in AKI due to primary elimination by the kidneys 1

Avoid concomitant administration of multiple nephrotoxic medications in patients with AKI, as recommended by the National Kidney Foundation 2
When AKI is diagnosed, consider temporarily holding other medications that may worsen kidney function, such as NSAIDs, ACE inhibitors, ARBs, and diuretics, as suggested by the American Gastroenterological Association 3
Be aware that diuretics and ACE inhibitors are associated with an increased risk of AKI, with a hazard ratio of 1.64 and 1.39, respectively, although the exact citation for this data is not provided, the recommendation to avoid nephrotoxic medications is supported by 2 and 3